239 related articles for article (PubMed ID: 35605249)
21. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
[TBL] [Abstract][Full Text] [Related]
22. Global Proteomic Changes Induced by the Epstein-Barr Virus Oncoproteins Latent Membrane Protein 1 and 2A.
DeKroon RM; Gunawardena HP; Edwards R; Raab-Traub N
mBio; 2018 Jun; 9(3):. PubMed ID: 29921667
[TBL] [Abstract][Full Text] [Related]
23. Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
Cen O; Kannan K; Huck Sappal J; Yu J; Zhang M; Arikan M; Ucur A; Ustek D; Cen Y; Gordon L; Longnecker R
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135222
[TBL] [Abstract][Full Text] [Related]
24. A new model of LMP1-MYC interaction in B cell lymphoma.
Ontiveros EP; Halwani A; Stunz LL; Kamberos N; Olivier AK; Janz S; Bishop GA
Leuk Lymphoma; 2014 Dec; 55(12):2917-23. PubMed ID: 24605938
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice.
Vrazo AC; Chauchard M; Raab-Traub N; Longnecker R
PLoS Pathog; 2012; 8(4):e1002662. PubMed ID: 22536156
[TBL] [Abstract][Full Text] [Related]
26. EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression.
Guasparri I; Bubman D; Cesarman E
Blood; 2008 Apr; 111(7):3813-20. PubMed ID: 18230756
[TBL] [Abstract][Full Text] [Related]
27. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?
Allday MJ
Semin Cancer Biol; 2009 Dec; 19(6):366-76. PubMed ID: 19635566
[TBL] [Abstract][Full Text] [Related]
28. Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III.
Messinger JE; Dai J; Stanland LJ; Price AM; Luftig MA
mBio; 2019 Jul; 10(4):. PubMed ID: 31266868
[TBL] [Abstract][Full Text] [Related]
29. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.
Polack A; Hörtnagel K; Pajic A; Christoph B; Baier B; Falk M; Mautner J; Geltinger C; Bornkamm GW; Kempkes B
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10411-6. PubMed ID: 8816814
[TBL] [Abstract][Full Text] [Related]
30. Transcriptome changes induced by Epstein-Barr virus LMP1 and LMP2A in transgenic lymphocytes and lymphoma.
Shair KH; Raab-Traub N
mBio; 2012; 3(5):. PubMed ID: 22991431
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr Virus-Encoded Latent Membrane Protein 1 and B-Cell Growth Transformation Induce Lipogenesis through Fatty Acid Synthase.
Hulse M; Johnson SM; Boyle S; Caruso LB; Tempera I
J Virol; 2021 Jan; 95(4):. PubMed ID: 33208446
[TBL] [Abstract][Full Text] [Related]
32. Tumor Suppressor p53 Stimulates the Expression of Epstein-Barr Virus Latent Membrane Protein 1.
Wang Q; Lingel A; Geiser V; Kwapnoski Z; Zhang L
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794023
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus encoded latent membrane protein 1 (LMP1) and TNF receptor associated factors (TRAF): colocalisation of LMP1 and TRAF1 in primary EBV infection and in EBV associated Hodgkin lymphoma.
Siegler G; Kremmer E; Gonnella R; Niedobitek G
Mol Pathol; 2003 Jun; 56(3):156-61. PubMed ID: 12782762
[TBL] [Abstract][Full Text] [Related]
34. l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.
Sang W; Tu D; Zhang M; Qin Y; Yin W; Song X; Sun C; Yan D; Wang X; Zeng L; Li Z; Xu K; Xu L
J Biochem Mol Toxicol; 2022 Aug; 36(8):e23117. PubMed ID: 35757978
[TBL] [Abstract][Full Text] [Related]
35. Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo.
Cherney BW; Sgadari C; Kanegane C; Wang F; Tosato G
Blood; 1998 Apr; 91(7):2491-500. PubMed ID: 9516150
[TBL] [Abstract][Full Text] [Related]
36. Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease.
Minamitani T; Ma Y; Zhou H; Kida H; Tsai CY; Obana M; Okuzaki D; Fujio Y; Kumanogoh A; Zhao B; Kikutani H; Kieff E; Gewurz BE; Yasui T
Proc Natl Acad Sci U S A; 2017 May; 114(18):4751-4756. PubMed ID: 28351978
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene.
Fries KL; Miller WE; Raab-Traub N
J Virol; 1996 Dec; 70(12):8653-9. PubMed ID: 8970991
[TBL] [Abstract][Full Text] [Related]
38. LMP1 and EBNA2 constitute a minimal set of EBV genes for transformation of human B cells.
Zhang J; Sommermann T; Li X; Gieselmann L; de la Rosa K; Stecklum M; Klein F; Kocks C; Rajewsky K
Front Immunol; 2023; 14():1331730. PubMed ID: 38169736
[TBL] [Abstract][Full Text] [Related]
39. Targeting latent viral infection in EBV-associated lymphomas.
Kong IY; Giulino-Roth L
Front Immunol; 2024; 15():1342455. PubMed ID: 38464537
[TBL] [Abstract][Full Text] [Related]
40. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer.
Pang MF; Lin KW; Peh SC
Cell Mol Biol Lett; 2009; 14(2):222-47. PubMed ID: 19082921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
